Matching articles for "Elevidys"
Givinostat (Duvyzat) for Duchenne Muscular Dystrophy
Givinostat ( Duvyzat – Italfarmaco), an oral histone deacetylase inhibitor, has been approved by the FDA for treatment of patients ≥6 years old with Duchenne muscular dystrophy (DMD), regardless of the…
Med Lett Drugs Ther. 2024 Dec 23; 66(1718):204-5 doi:10.58347/tml.2024.1718c
Givinostat ( Duvyzat – Italfarmaco), an oral histone deacetylase inhibitor, has been approved by the FDA for treatment of patients ≥6 years old with Duchenne muscular dystrophy (DMD), regardless of the DMD-causing mutation. It is the first nonsteroidal drug to be approved for this indication. The oral corticosteroids deflazacort (Emflaza) and vamorolone (Agamree) are also approved for treatment of patients with all genetic variants of DMD.
In Brief: Expanded Indication for Elevidys
The adeno-associated virus (AAV) vector-based gene therapy delandistrogene moxeparvovec-rokl ( Elevidys – Sarepta) received accelerated approval from the FDA in 2023 for treatment of ambulatory children 4-5…
Med Lett Drugs Ther. 2024 Aug 19; 66(1709):135-6 doi:10.58347/tml.2024.1709e
The adeno-associated virus (AAV) vector-based gene therapy delandistrogene moxeparvovec-rokl ( Elevidys – Sarepta) received accelerated approval from the FDA in 2023 for treatment of ambulatory children 4-5 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene. It has now received full approval for use in ambulatory patients ≥4 years old and accelerated approval for use in nonambulatory patients with DMD.
Delandistrogene Moxeparvovec (Elevidys) for Duchenne Muscular Dystrophy
Delandistrogene moxeparvovec-rokl ( Elevidys – Sarepta), an adeno-associated virus (AAV) vector-based gene therapy, has received accelerated approval from the FDA for treatment of ambulatory children 4-5…
Med Lett Drugs Ther. 2023 Oct 2; 65(1686):159-60 doi:10.58347/tml.2023.1686d
Delandistrogene moxeparvovec-rokl ( Elevidys – Sarepta), an adeno-associated virus (AAV) vector-based gene therapy, has received accelerated approval from the FDA for treatment of ambulatory children 4-5 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene. It is the first gene therapy to be approved in the US for treatment of DMD. Accelerated approval was based on expression of microdystrophin in skeletal muscle, a surrogate endpoint.
